Law360, New York (July 31, 2007, 12:00 AM ET) -- After a contentious day of hearings, a panel of U.S. Food and Drug Administration advisers has overwhelmingly voted to keep Avandia on the market despite data that suggests the controversial diabetes drug leads to more cardiovascular risks.
On Tuesday, the FDA panel voted 22 to 1 to recommend that GlaxoSmithKline's Avandia remain on the market, setting aside widespread outcry from consumers and medical professionals that the medication is unsafe.
While the panel acknowledged that evidence did show an increased risk of heart attack in some Avandia...
Avandia Survives Scrutiny From FDA Panel
To view the full article, take a free trial now.
